Radioimmunotherapy Phase I Dose-Escalation Studies in Prostate Cancer using 177Lu-J591 Antibody: Dose Fractionation Regimen

Study Status

Open to Enrollment

Study Description

The purpose of this study is to test the safety of the experimental drug 177Lu-J591 and see what effects (good and bad) it has on your prostate cancer. Another purpose is to find the highest dose of the drug that can be given without causing severe side effects.

Patients will receive two doses of the study drug 2 weeks apart. The dose of LuJ591 will remain fixed at a total dose of 20 mg/dose. The 177Lu dose will be escalated depending on which arm of the study you are enrolled in and how many patients have been included in the study at the time you enroll.  The amount of radioactivity you receive depends on your height and weight.

Disease Status and/or Stage

Metastatic Prostate Cancer


Weill Cornell Medical College

Key Eligibility

  • Men age 21 to 85
  • Progressive, castrate metastatic prostate cancer as shown by presence of metastatic disease on imaging and at least one of the following:
    • Progressive tumor lesions on CT or MRI
    • New osseus lesions on bone scan and/or
    • Rising PSA
  • Patients must not have had cytotoxic chemotherapy and/or radiation therapy within 4 weeks of study treatment
  • Additional eligibility discussed when you contact the study team

Principal Investigator

Scott Tagawa, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page